PTPRC and cancer: As is shown in Fig. 4B, radio-resistant A172 and GBM2 cancer cells harbor 21.6 and 39.0% of CD133+, 52.4 and 46.5% of CD117+, 51.2 and 37.6% of CD45+, 43.4 and 36.2% of CD71+ cells, respectively.